April 9, 2018 / 1:09 PM / 15 days ago

BRIEF-AbbVie Says Upadacitinib Met All Primary And Ranked Secondary Endpoints In Phase 3 Study In Rheumatoid Arthritis

April 9 (Reuters) - AbbVie Inc:

* UPADACITINIB MEETS ALL PRIMARY AND RANKED SECONDARY ENDPOINTS INCLUDING SUPERIORITY VERSUS ADALIMUMAB IN PHASE 3 STUDY IN RHEUMATOID ARTHRITIS

* ALL RANKED SECONDARY ENDPOINTS ALSO MET IN PHASE 3 STUDY IN RHEUMATOID ARTHRITIS

* PLANS GLOBAL REGULATORY SUBMISSIONS FOR UPADACITINIB IN RHEUMATOID ARTHRITIS IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below